Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial.
作者： Owen A. O'Connor , Tamás Masszi , Kerry J. Savage , Lauren C. Pinter-Brown , Francine M. Foss
DOI: 10.1200/JCO.2013.31.15_SUPPL.8507
关键词:
摘要: 8507 Background: Therapies approved in US for R/R PTCL have overall response rates (ORR) of 25%-27%. The need new therapies persists. BELIEF is a pivotal, single-arm study belinostat pati...
sci-hub.st 参考文章(0)